/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...
/PRNewswire/ -- The Law Offices of Frank R. Cruz announces an investigation of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX) on behalf of...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are...
/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...
Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis....
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions